Medartis Holding AGMDRSF 82 Return-on-Tangible-Equity is 16.73% as of Dec. 2025, which is 867% above its 10-year median of 1.73. GuruFocus rates MDRSF with a GF Score™ of 82/100 and a GF Value™ of $151.13. The stock has 5 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Medartis Holding AG ranks better than 53.17% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medartis Holding AG's annualized net income for the quarter that ended in Dec. 2025 was $24.6 Mil. Medartis Holding AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $147.0 Mil. Therefore, Medartis Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 16.73%.
The historical rank and industry rank for Medartis Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
MDRSF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.04 Med: 1.73 Max: 7.12
Current: 5.49
During the past 12 years, Medartis Holding AG's highest Return-on-Tangible-Equity was 7.12%. The lowest was -3.04%. And the median was 1.73%.
MDRSF's Return-on-Tangible-Equity is ranked better than 53.17% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs MDRSF: 5.49
Medartis Holding AG (OTCPK:MDRSF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medartis Holding AG Return-on-Tangible-Equity Related Terms
Medartis Holding AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG Return-on-Tangible-Equity Chart
MDRSF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Medartis Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.73% mean?
Medartis Holding AG (MDRSF) has a Return-on-Tangible-Equity of 16.73% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medartis Holding AG and its competitors. This is 867% above median its historical median of 1.73. According to the industry distribution chart, Medartis Holding AG ranks #355 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 46.8%.
Is Medartis Holding AG's Return-on-Tangible-Equity too high?
Medartis Holding AG's current Return-on-Tangible-Equity of 16.73% is 867% above median its 10-year median of 1.73. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Medartis Holding AG's value of 16.73% is 310% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #355 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medartis Holding AG has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #355 out of 758 companies for Return-on-Tangible-Equity. This puts Medartis Holding AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Medartis Holding AG's value of 16.73% is 310% above this benchmark. While the company's 10-year median is 1.73 vs. the industry median of 4.08, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current Return-on-Tangible-Equity of 16.73% is 310% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medartis Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current Return-on-Tangible-Equity is 16.73%, which is 867% above median its own 10-year median of 1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Medartis Holding AG (MDRSF) has a current Return-on-Tangible-Equity of 16.73%. The stock's GF Value™ is $151.13, compared to a current price of $115.00 — trading 23.9% below its estimated fair value. The current Return-on-Tangible-Equity is 16.73%, which is 867% above median its 10-year median of 1.73 and 310% above the Medical Devices & Instruments industry median of 4.08. Medartis Holding AG's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medartis Holding AG (MDRSF), the current Return-on-Tangible-Equity is 16.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (MDRSF) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of $115.00 is trading 23.9% below its estimated GF Value™ of $151.13.
Key valuation signals for MDRSF:
Return-on-Tangible-Equity: 16.73% (867% above median its 10-year median of 1.73)
GF Value™: $151.13 vs. price of $115.00 (23.9% below fair value)
Industry Position: 310% above the Medical Devices & Instruments median (#355 of 758)
No single metric tells the full story. See the MDRSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
82GF Score
Get the complete analysis for MDRSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDRSF has been successfully added to your 
